FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2479426178> ?p ?o ?g. }

• W2479426178 endingPage "56888" @default.
• W2479426178 startingPage "56876" @default.
• W2479426178 abstract "// Ameet K. Mishra 1 , Annelie Abrahamsson 1 , Charlotta Dabrosin 1 1 Department of Oncology and Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden Correspondence to: Charlotta Dabrosin, email: charlotta.dabrosin@liu.se Keywords: mammary cancer, sex steroids, steroid receptors, proliferation, DNA methyltransferase Received: October 30, 2015      Accepted: July 16, 2016      Published: July 28, 2016 ABSTRACT The estrogen receptor-alpha (ERα) is used as a predictive marker for anti-estrogen therapy in breast cancer patients. In addition to aromatase inhibitors, ERα can be targeted at the receptor level using the receptor modulator tamoxifen or by the pure anti-estrogen fulvestrant. The role of the second ER, ER-beta (ERβ), as a therapeutic target or prognostic marker in breast cancer is still elusive. Hitherto, it is not known if ERα+/ERβ+ breast cancers would benefit from a treatment strategy combining tamoxifen and fulvestrant or if fulvestrant exert any therapeutic effects in ERα-/ERβ+ breast cancer. Here, we report that fulvestrant up-regulated ERβ in ERα+/ERβ+ breast cancer and in triple negative ERβ+ breast cancers (ERα-/ERβ+). In ERα+/ERβ+ breast cancer, a combination therapy of tamoxifen and fulvestrant significantly reduced tumor growth compared to either treatment alone both in vivo and in vitro. In ERα-/ERβ+ breast cancer fulvestrant had potent effects on cancer growth, in vivo as well as in vitro , and this effect was dependent on intrinsically expressed levels of ERβ. The role of ERβ was further confirmed in cells where ERβ was knocked-in or knocked-down. Inhibition of DNA methyltransferase (DNMT) increased the levels of ERβ and fulvestrant exerted similar potency on DNMT activity as the DNMT inhibitor decitabine. We conclude that fulvestrant may have therapeutic potential in additional groups of breast cancer patients; i) in ERα+/ERβ+ breast cancer where fulvestrant synergizes with tamoxifen and ii) in triple negative/ERβ+ breast cancer patients, a subgroup of breast cancer patients with poor prognosis." @default.
• W2479426178 created "2016-08-23" @default.
• W2479426178 creator A5004664653 @default.
• W2479426178 creator A5011260253 @default.
• W2479426178 creator A5079839249 @default.
• W2479426178 date "2016-07-28" @default.
• W2479426178 modified "2023-10-14" @default.
• W2479426178 title "Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ" @default.
• W2479426178 cites W1453600927 @default.
• W2479426178 cites W1538903611 @default.
• W2479426178 cites W1900170853 @default.
• W2479426178 cites W1965890948 @default.
• W2479426178 cites W1968847679 @default.
• W2479426178 cites W1969346276 @default.
• W2479426178 cites W1970136017 @default.
• W2479426178 cites W1973730551 @default.
• W2479426178 cites W1975740303 @default.
• W2479426178 cites W1979849644 @default.
• W2479426178 cites W1982035170 @default.
• W2479426178 cites W1987598375 @default.
• W2479426178 cites W1987608812 @default.
• W2479426178 cites W1992094512 @default.
• W2479426178 cites W2002824365 @default.
• W2479426178 cites W2003627629 @default.
• W2479426178 cites W2004865397 @default.
• W2479426178 cites W2013956549 @default.
• W2479426178 cites W2014849723 @default.
• W2479426178 cites W2017207536 @default.
• W2479426178 cites W2019039003 @default.
• W2479426178 cites W2020508605 @default.
• W2479426178 cites W2021383412 @default.
• W2479426178 cites W2022413718 @default.
• W2479426178 cites W2022792151 @default.
• W2479426178 cites W2028950695 @default.
• W2479426178 cites W2029957836 @default.
• W2479426178 cites W2032172396 @default.
• W2479426178 cites W2034001757 @default.
• W2479426178 cites W2036334064 @default.
• W2479426178 cites W2047485440 @default.
• W2479426178 cites W2049167941 @default.
• W2479426178 cites W2053213384 @default.
• W2479426178 cites W2053385718 @default.
• W2479426178 cites W2054372078 @default.
• W2479426178 cites W2055226527 @default.
• W2479426178 cites W2061057693 @default.
• W2479426178 cites W2067313784 @default.
• W2479426178 cites W2073353512 @default.
• W2479426178 cites W2073883348 @default.
• W2479426178 cites W2080503494 @default.
• W2479426178 cites W2081804058 @default.
• W2479426178 cites W2083426370 @default.
• W2479426178 cites W2089094422 @default.
• W2479426178 cites W2104561097 @default.
• W2479426178 cites W2106032229 @default.
• W2479426178 cites W2113907939 @default.
• W2479426178 cites W2118388990 @default.
• W2479426178 cites W2118728607 @default.
• W2479426178 cites W2126982762 @default.
• W2479426178 cites W2136833945 @default.
• W2479426178 cites W2139517025 @default.
• W2479426178 cites W2147208780 @default.
• W2479426178 cites W2161623422 @default.
• W2479426178 cites W2170602872 @default.
• W2479426178 cites W4205406915 @default.
• W2479426178 doi "https://doi.org/10.18632/oncotarget.10871" @default.
• W2479426178 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5302959" @default.
• W2479426178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27486755" @default.
• W2479426178 hasPublicationYear "2016" @default.
• W2479426178 type Work @default.
• W2479426178 sameAs 2479426178 @default.
• W2479426178 citedByCount "37" @default.
• W2479426178 countsByYear W24794261782017 @default.
• W2479426178 countsByYear W24794261782018 @default.
• W2479426178 countsByYear W24794261782019 @default.
• W2479426178 countsByYear W24794261782020 @default.
• W2479426178 countsByYear W24794261782021 @default.
• W2479426178 countsByYear W24794261782022 @default.
• W2479426178 countsByYear W24794261782023 @default.
• W2479426178 crossrefType "journal-article" @default.
• W2479426178 hasAuthorship W2479426178A5004664653 @default.
• W2479426178 hasAuthorship W2479426178A5011260253 @default.
• W2479426178 hasAuthorship W2479426178A5079839249 @default.
• W2479426178 hasBestOaLocation W24794261781 @default.
• W2479426178 hasConcept C121608353 @default.
• W2479426178 hasConcept C126322002 @default.
• W2479426178 hasConcept C143998085 @default.
• W2479426178 hasConcept C172313692 @default.
• W2479426178 hasConcept C2776067312 @default.
• W2479426178 hasConcept C2776166826 @default.
• W2479426178 hasConcept C2777176818 @default.
• W2479426178 hasConcept C2780482068 @default.
• W2479426178 hasConcept C502942594 @default.
• W2479426178 hasConcept C530470458 @default.
• W2479426178 hasConcept C71924100 @default.
• W2479426178 hasConcept C84606932 @default.
• W2479426178 hasConceptScore W2479426178C121608353 @default.
• W2479426178 hasConceptScore W2479426178C126322002 @default.
• W2479426178 hasConceptScore W2479426178C143998085 @default.

• next